WCG has launched Total Safety, an end-to-end solution for case processing, aggregate safety reporting, drug safety and safety letter distribution.

The system is designed to reduce burden on sites imposed by safety document reviews and helps up-and-coming biopharma companies avoid having to create their own internal drug safety systems. In addition, Total Safety stores data from study sites and CROs in a single safety database in real-time.

“We have reengineered the industry’s status quo safety management process — which is intricate, onerous and risky — and simplified it in a manner that facilitates increased protections for patients, stronger regulatory compliance and less burden on investigators and staff in the clinical trial process,” Nicholas Slack, president of WCG, said. “Leaving safety to chance is a risky proposition for all organizations, especially earlier-stage biopharmaceutical companies.”

According to WCG, the full system has not been released until now, but clients have used components of the Total Safety solution previously and seen noteworthy results, including $40,000 saved per study on average and reductions of up to 50 percent on unnecessary safety reports.